James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
|Articles|April 4, 2008
GSK revises Relenza prescribing information to warn of abnormal behavior
GlaxoSmithKline updates Warnings and Precautions sections of zanamivir prescribing information
Advertisement
GSK revises Relenza prescribing information to warn of abnormal behaviorPostmarketing reports of delirium and abnormal behavior in patients with influenza who are receiving neuraminidase inhibitors have prompted GlaxoSmithKline to update the prescribing information for zanamivir (
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.
In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.
A study found that age and physical comorbidities—not psychiatric diagnosis—were associated with nonpsychotropic polypharmacy.
Advertisement
Advertisement
Trending on Drug Topics
1
GLP-1 Prescribing Rose Among Adults With Serious Mental Illness
2
Scripted for Her: The Pharmacist's Role in HPV Prevention
3
AI, Automation Are Transforming Pharmacies into Proactive Care Hubs
4
FDA Approves Finerenone for Chronic Kidney Disease With Type 1 Diabetes
5